rat monoclonal anti cd34 antibody  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells"

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    Journal: bioRxiv

    doi: 10.1101/2023.01.08.523169

    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Figure Legend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Techniques Used: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    rat monoclonal anti cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells"

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    Journal: bioRxiv

    doi: 10.1101/2023.01.08.523169

    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Figure Legend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Techniques Used: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    mouse monoclonal anti cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech mouse monoclonal anti cd34 antibody
    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti <t>CD34</t> antibodies. Angiogenesis was quantified by image analysis of <t>CD34</t> <t>positive</t> stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Mouse Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2"

    Article Title: Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0044351

    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Figure Legend Snippet: Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Techniques Used: Injection, Isolation, Staining, Software

    mouse monoclonal anti cd34  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech mouse monoclonal anti cd34
    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti <t>CD34</t> antibodies. Angiogenesis was quantified by image analysis of <t>CD34</t> <t>positive</t> stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Mouse Monoclonal Anti Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti cd34/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti cd34 - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2"

    Article Title: Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0044351

    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Figure Legend Snippet: Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Techniques Used: Injection, Isolation, Staining, Software

    anti cd34 monoclonal antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech anti cd34 monoclonal antibody
    ( A ) Serial changes of ki67 positivity until 7 days after each irradiation (** P < 0.01, *** P < 0.005). ( B ) Microphotographs of tumor tissues immunohistochemically stained by <t>anti-CD34</t> monoclonal antibody. ( C ) Serial changes of <t>CD34-positive</t> area until 7 days after each irradiation (* P < 0.05, *** P < 0.005).
    Anti Cd34 Monoclonal Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd34 monoclonal antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cd34 monoclonal antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    1) Product Images from "Generation of low-flux X-ray micro-planar beams and their biological effect on a murine subcutaneous tumor model"

    Article Title: Generation of low-flux X-ray micro-planar beams and their biological effect on a murine subcutaneous tumor model

    Journal: Journal of Radiation Research

    doi: 10.1093/jrr/rrv037

    ( A ) Serial changes of ki67 positivity until 7 days after each irradiation (** P < 0.01, *** P < 0.005). ( B ) Microphotographs of tumor tissues immunohistochemically stained by anti-CD34 monoclonal antibody. ( C ) Serial changes of CD34-positive area until 7 days after each irradiation (* P < 0.05, *** P < 0.005).
    Figure Legend Snippet: ( A ) Serial changes of ki67 positivity until 7 days after each irradiation (** P < 0.01, *** P < 0.005). ( B ) Microphotographs of tumor tissues immunohistochemically stained by anti-CD34 monoclonal antibody. ( C ) Serial changes of CD34-positive area until 7 days after each irradiation (* P < 0.05, *** P < 0.005).

    Techniques Used: Irradiation, Staining

    rat anti mouse cd34 mab  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 mab
    Rat Anti Mouse Cd34 Mab, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 mab/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 mab - by Bioz Stars, 2024-04
    86/100 stars

    Images

    rat anti mouse cd34 mab  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 mab
    Rat Anti Mouse Cd34 Mab, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 mab/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 mab - by Bioz Stars, 2024-04
    86/100 stars

    Images

    rat anti mouse cd34 mab  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 mab
    Rat Anti Mouse Cd34 Mab, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 mab/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 mab - by Bioz Stars, 2024-04
    86/100 stars

    Images

    anti cd34 monoclonal antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Hycult Biotech anti cd34 monoclonal antibody
    Anti Cd34 Monoclonal Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd34 monoclonal antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cd34 monoclonal antibody - by Bioz Stars, 2024-04
    93/100 stars

    Images

    monoclonal rat anti mouse cd34 antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech monoclonal rat anti mouse cd34 antibody
    Monoclonal Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    86/100 stars

    Images

    rat anti mouse cd34 monoclonal antibody  (Hycult Biotech)


    Bioz Verified Symbol Hycult Biotech is a verified supplier
    Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Hycult Biotech rat anti mouse cd34 monoclonal antibody
    Rat Anti Mouse Cd34 Monoclonal Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 monoclonal antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 monoclonal antibody - by Bioz Stars, 2024-04
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Hycult Biotech rat monoclonal anti cd34 antibody
    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, <t>CD34</t> and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.
    Rat Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech mouse monoclonal anti cd34 antibody
    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti <t>CD34</t> antibodies. Angiogenesis was quantified by image analysis of <t>CD34</t> <t>positive</t> stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Mouse Monoclonal Anti Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti cd34 antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti cd34 antibody - by Bioz Stars, 2024-04
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech mouse monoclonal anti cd34
    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti <t>CD34</t> antibodies. Angiogenesis was quantified by image analysis of <t>CD34</t> <t>positive</t> stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).
    Mouse Monoclonal Anti Cd34, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti cd34/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti cd34 - by Bioz Stars, 2024-04
    93/100 stars
      Buy from Supplier

    93
    Hycult Biotech anti cd34 monoclonal antibody
    ( A ) Serial changes of ki67 positivity until 7 days after each irradiation (** P < 0.01, *** P < 0.005). ( B ) Microphotographs of tumor tissues immunohistochemically stained by <t>anti-CD34</t> monoclonal antibody. ( C ) Serial changes of <t>CD34-positive</t> area until 7 days after each irradiation (* P < 0.05, *** P < 0.005).
    Anti Cd34 Monoclonal Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd34 monoclonal antibody/product/Hycult Biotech
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cd34 monoclonal antibody - by Bioz Stars, 2024-04
    93/100 stars
      Buy from Supplier

    86
    Hycult Biotech rat anti mouse cd34 mab
    ( A ) Serial changes of ki67 positivity until 7 days after each irradiation (** P < 0.01, *** P < 0.005). ( B ) Microphotographs of tumor tissues immunohistochemically stained by <t>anti-CD34</t> monoclonal antibody. ( C ) Serial changes of <t>CD34-positive</t> area until 7 days after each irradiation (* P < 0.05, *** P < 0.005).
    Rat Anti Mouse Cd34 Mab, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 mab/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 mab - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    86
    Hycult Biotech monoclonal rat anti mouse cd34 antibody
    ( A ) Serial changes of ki67 positivity until 7 days after each irradiation (** P < 0.01, *** P < 0.005). ( B ) Microphotographs of tumor tissues immunohistochemically stained by <t>anti-CD34</t> monoclonal antibody. ( C ) Serial changes of <t>CD34-positive</t> area until 7 days after each irradiation (* P < 0.05, *** P < 0.005).
    Monoclonal Rat Anti Mouse Cd34 Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal rat anti mouse cd34 antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal rat anti mouse cd34 antibody - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    86
    Hycult Biotech rat anti mouse cd34 monoclonal antibody
    ( A ) Serial changes of ki67 positivity until 7 days after each irradiation (** P < 0.01, *** P < 0.005). ( B ) Microphotographs of tumor tissues immunohistochemically stained by <t>anti-CD34</t> monoclonal antibody. ( C ) Serial changes of <t>CD34-positive</t> area until 7 days after each irradiation (* P < 0.05, *** P < 0.005).
    Rat Anti Mouse Cd34 Monoclonal Antibody, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rat anti mouse cd34 monoclonal antibody/product/Hycult Biotech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rat anti mouse cd34 monoclonal antibody - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    Image Search Results


    Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Journal: bioRxiv

    Article Title: DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells

    doi: 10.1101/2023.01.08.523169

    Figure Lengend Snippet: Antitumor activity of DiPRO1 inhibitors in the Ewing sarcoma (EW) subcutaneous tumor xenograft model. Nude mice received s.c. inoculations of A673 Ewing sarcoma cells and were treated with siDiPRO1/jetPEI® and shDiPRO1/jetPEI® nanocomposites or siCtl/jetPEI® scramble (Ctl) at a dose of 0.5 or 1 mg/kg/d. The initial tumor volume on the day of treatment initiation was V0=168±76 mm3 in the first (EW1; n=7 mice per group) and V0=71±24 mm3 in the second (EW2) and third (EW3) independent experiments (n=5 mice per group). A, Uptake by tumor cells of siDiPRO1/jetPEI®/Cy5 nanocomposites. Internalization was followed in live mice (video; lower panel) treated with a single dose (0.5 mg/kg) of Cy5-coupled anti-DiPRO1 siRNA complexes and in extracted tumors (upper panel) 24 h and 72 h after treatment. Control mice were treated with an equimolar dose of non-targeted siCtl/jetPEI® free of Cy5. B, DiPRO1 depletion efficiency in tumors was verified by RT-qPCR. DiPRO1 mRNA expression levels in three independent experiments were normalized to GAPDH, n=9, mean ± SD. DiPRO1 expression in control tumors was referenced to 100%. Statistical analysis was performed using the t -test. C, Tumor progression was compared between the indicated groups (V n /V 0 ). Results from three independent experiments are presented. Two-way ANOVA test was used for statistical analysis at the indicated time points. D, A nalysis of main endpoints of antitumor activity of the si/hDiPRO1 and control nanomedicines against human Ewing sarcoma xenografts. E, Effect of DiPRO1 inhibition on survival of tumor-bearing mice. Kaplan-Meier curves of overall survival for 43 days (n = 12) from the day of xenograft implantation are shown. Log-Rank test (Mantel-Cox) for each pairwise comparison (treatment vs. control) was applied for statistical analysis. Results from two independent experiments (EW1 and EW2) are combined. F, Assessment of body weight loss (BWL) in mice bearing tumor xenografts. The results of two independent experiments (EW1 and EW2) are combined. G, Immunohistochemical staining of excised tumor tissues at day 12. Representative images of tumor sections stained with hematoxylin/eosin/safranin (HES) (arrows indicate striated muscle), and cells positive for internal and peripheral caspase-3 (Cas-3 periph, indicated by arrows), Ki-67, CD34 and TUNEL are shown. H, Quantitative analysis of positively immunostained cells (%) relative to the total number of tumor cells. Six to eleven fields were selected for counting. Necrotic fields were excluded. C, F: All box-plots and growth curves are displayed as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, P values are shown between indicated groups and appropriate controls.

    Article Snippet: Polyclonal rabbit anti-MCM6 (Proteintech, 13347-2-AP) and polyclonal rabbit anti-TIF1B/KAP1 (Merck Millipore, Sigma-Aldrich, ABE1859), mouse monoclonal anti-ICBP90/UHRF1 (Sigma-Aldrich, MABE308), rat monoclonal anti-HA-Peroxidase high affinity (Roche, Sigma-Aldrich, 12013819001), rabbit polyclonal anti-Actin (Sigma-Aldrich, A2103), mouse monoclonal anti-FLAG® M2-Peroxidase (Sigma-Aldrich, A8592), mouse monoclonal anti-Tropomyosin Ab (Sigma-Aldrich, T2780), goat polyclonal anti-rabbit IgG–Peroxidase antibody (Sigma-Aldrich, A6154), Alexa Fluor® 488 Goat Anti-Mouse IgG antibody (Molecular Probes, Invitrogen, A-11001, A11029), Alexa Fluor® 594 Goat Anti-Rabbit IgG antibody (Molecular Probes, Invitrogen, A-11012), Fluoroshield™ with DAPI (Sigma-Aldrich, F6057), Dynabeads™ CD25 (Invitrogen, Thermo Ficher Scientific, 11157D), rat monoclonal anti-CD34 antibody (HycultBiotech, HM1015), Polink-2 Plus HRP Rat-NM Bulk kit for DAB (GBI Labs, D46-110), rabbit monoclonal anti-Ki67 (Neomarkers; LabVision, Thermo Fisher Scientific, RM-9106), rabbit polyclonal cleaved Caspase-3 (Asp175) (Cell Signaling, 9661), anti-FLAG M2 affinity gel (Sigma-Aldrich, A 2220), FLAG® Peptide (Sigma-Aldrich, F3290), Protein A agarose (Pierce, Thermo Ficher Scientific, 20333).

    Techniques: Activity Assay, Quantitative RT-PCR, Expressing, Inhibition, Immunohistochemical staining, Staining, TUNEL Assay

    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Journal: PLoS ONE

    Article Title: Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2

    doi: 10.1371/journal.pone.0044351

    Figure Lengend Snippet: Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Article Snippet: To visualize endothelial cells within the tumors, sections were incubated with mouse monoclonal anti-CD34 antibody (Hycult Biotech, The Netherlands) during 1 hour at 37°C in a humidity chamber.

    Techniques: Injection, Isolation, Staining, Software

    Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Journal: PLoS ONE

    Article Title: Antitumor and Angiostatic Activities of the Antimicrobial Peptide Dermaseptin B2

    doi: 10.1371/journal.pone.0044351

    Figure Lengend Snippet: Treatment of xenografted nude mice was started thirteen days after s.c. PC3 cell injection. Experimental group (n = 8) was treated six times per week p.t. with 100 µL Drs B2 (2.5 mg/kg body weight). Control group (n = 7) was treated six times per week p.t. with 100 µL of PBS. A ) The effect of Drs B2 on tumor size versus time of treatment. After 47 days of treatment the mice were sacrificed, body weight was observed; tumors were isolated, B ) weighted and stored at −80°C. C ) PC3 tumor proliferation was evaluated by Ki67 staining of frozen tissue sections. Proliferation was quantified by image J software analysis of Ki67 positive stained cells on the whole tumor section. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm. * p <0.05 versus control (PBS). D ) Tumor vessel formation was observed with anti CD34 antibodies. Angiogenesis was quantified by image analysis of CD34 positive stained endothelial cells. The data are mean areas ± SD obtained from 6 control mice and 4 mice treated with Drs B2. Scale bar, 50 µm * p <0.05 versus control (PBS).

    Article Snippet: Mouse monoclonal anti-CD34 was from Hycult Biotech (The Netherlands), secondary antibody, rabbit anti-rat IgG was obtained from Southern Biotech (Clinisciences; France).

    Techniques: Injection, Isolation, Staining, Software

    ( A ) Serial changes of ki67 positivity until 7 days after each irradiation (** P < 0.01, *** P < 0.005). ( B ) Microphotographs of tumor tissues immunohistochemically stained by anti-CD34 monoclonal antibody. ( C ) Serial changes of CD34-positive area until 7 days after each irradiation (* P < 0.05, *** P < 0.005).

    Journal: Journal of Radiation Research

    Article Title: Generation of low-flux X-ray micro-planar beams and their biological effect on a murine subcutaneous tumor model

    doi: 10.1093/jrr/rrv037

    Figure Lengend Snippet: ( A ) Serial changes of ki67 positivity until 7 days after each irradiation (** P < 0.01, *** P < 0.005). ( B ) Microphotographs of tumor tissues immunohistochemically stained by anti-CD34 monoclonal antibody. ( C ) Serial changes of CD34-positive area until 7 days after each irradiation (* P < 0.05, *** P < 0.005).

    Article Snippet: Then, they were incubated with an anti-CD34 monoclonal antibody (Hycult Biotech, Uden, Netherlands) diluted by the blocking buffer of peroxidase detection reagent Pack (Thermo Fisher Scientific) for 2 h at 37°C and washed with PBS twice.

    Techniques: Irradiation, Staining